Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Regeneron, Bayer Cite Positive Eye Drug Study

By Pharmaceutical Processing | December 20, 2010

NEW YORK (AP) — Regeneron Pharmaceuticals Inc. and
Bayer HealthCare AG said todya their developing VEGF Trap-Eye drug met key
treatment goals in a late-stage study on macular edema patients.

Specifically, the study focused on patients with macular edema because of
central retinal vein occlusion, or blockage of retinal veins. Macular edema is a
condition in which the macula, or central part of the retina, swells because
fluid leaks or builds up.

In the 114-person study, the drug prompted vision improvements. The study
showed that 56.1 percent of patients receiving the injections on a monthly basis
gained at least 15 letters in vision tests. That compares with only 12.3 percent
of patients receiving placebo injections.

An additional late-stage study is ongoing.

Meanwhile, the company reported positive results from a midstage study
focusing on VEGF Trap-Eye’s use as a treatment for diabetic macular edema. The
condition is a disease of the retina that affects individuals with diabetes and
can lead to blindness.

Regeneron and Bayer are also developing the drug candidate as a treatment for
wet age-related macular degeneration, which results in vision loss as new blood
vessels grow beneath the retina and leak blood and fluid, damaging the retina
and distorting vision. The condition, which can progress to blindness, usually
affects older adults. The “dry” form of the condition is the most common type of
age-related macular degeneration, with the “wet” form considered the more
advanced version of the disease. There are up to 200,000 new cases for the “wet”
form of the condition each year in the U.S. Wet AMD is the leading cause of
blindness for people over the age of 65 in the U.S. and Europe.

The positive result in the macular edema indication triggers a $10 million
milestone payment for Regeneron from Bayer, in addition to a second $10 million
milestone Regeneron received earlier in the month for the wet AMD data.

The companies have said they plan to request European and U.S. regulatory
approval in the first half of 2011 for the “wet” form of the condition.

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE